#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Giant cell tumour of tendon sheath Orthostatic hypotension Rheumatoid arthritis Cytomegalovirus infection B precursor type acute leukaemia Anal fistula Chronic graft versus host disease in skin Infantile apnoea Neuroendocrine tumour of the lung Arteriosclerosis Myeloid leukaemia Leukaemia Congenital pseudarthrosis Penile cancer Polycythaemia vera More trials…

    Learn about Rare Diseases

    Congenital hypotransferrinaemia Hyperoxaluria – Trials in Disease Glycogen storage disease type II – Trials in Disease Systemic sclerosis pulmonary – Trials in Disease Sarcoma – Basic Information SAPHO syndrome – Life with Disease Advanced systemic mastocytosis – Trials in Disease Castleman’s disease – Treatment Anaplastic thyroid cancer Leukoencephalopathy – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Antithymocyte Immunoglobulin Cln-081 Zanubrutinib Atazanavir Enzalutamide ABBV-CLS-628 Cemiplimab Aon-D21 GSK3862995B Sodium Ascorbate Abrocitinib Canagliflozin Isavuconazonium Sulfate Vb10.16 Enomimeran Clopidogrel Crgd-Zw800-1 Bevacizumab Zirconium Zr-89 Paracetamol Ph. Eur. Tng462 More therapies…

    Learn about Your Condition

    Tardive dyskinesia Neurotrophic keratopathy Renal cancer stage IV Anal cancer metastatic Psoriatic arthropathy Migraine Plasmablastic lymphoma Prader-Willi syndrome Neurodermatitis Exudative retinopathy Lip and/or oral cavity cancer Choroid melanoma Post procedural oedema Relapsing multiple sclerosis Chronic spontaneous urticaria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

    Recruiting

    3 1
    Investigated Drugs:
    • Zasocitinib
    Belgium Bulgaria Croatia Czechia Estonia France +7
  • Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • Obicetrapib
    • Bempedoic Acid
    Czechia Germany Italy The Netherlands Poland Slovakia +1
  • A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Etoposide
    Austria Belgium Bulgaria Czechia Estonia Finland +14
  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Fallopian tube cancer
    • Ovarian cancer
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • LY4170156
    • Bevacizumab
    Austria Belgium Czechia Denmark France Germany +9
  • Evaluation of pembrolizumab and bevacizumab in patients with metastatic cervical cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Cervix carcinoma
    Investigated Drugs:
    • Bevacizumab
    • Pembrolizumab
    The Netherlands
  • Zongertinib for Cancer in Patients Eligible for Early Access Treatment

    Recruiting

    2 1 1
    Investigated Drugs:
    • Zongertinib
    Finland
Previous Page
1 … 16 17 18 19 20 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.


European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!